This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Amy Lugo, PharmD
Advertisement
Articles by Amy Lugo, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS
5